Study title: A Phase three, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of QPI-1002 for Prevention of Delayed Graft Function in Recipients of a Donation After Brain Death Older Donor Kidney Transplant
Note: This study has finished enrollment and Ohio State was one of the top 10 enrolling sites globally and the third highest enrolling site in the nation.
- Weblink to trial
- Principal investigator: Ashraf El-Hinnawi, MD
- Overview: Ohio State is one of the top ten enrolling centers in the U.S. for this phase three randomized, placebo-controlled, double-blind, multi-center trial stratified by donor age and by region to evaluate the reduction in incidence and severity of delayed graft function with kidney allografts from DBD donors who were at least 45 years of age